Clinical Trials Using Docetaxel

Clinical trials are research studies that involve people. The clinical trials on this list are studying Docetaxel. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 108

  • Trastuzumab, Pertuzumab, and Combination Chemotherapy in Treating Patients with Locally Advanced, Resectable, or Inflammatory Her2 Positive Breast Cancer

    This phase II trial studies how well two different anti-cancer treatment regimens which both contain trastuzumab and pertuzumab, but with different combinations of chemotherapy work in shrinking cancer before surgery in patients with localized Her2 positive breast cancer. Trastuzumab and pertuzumab are forms of “targeted therapy” because they work by attaching to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab or pertuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body’s immune system. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, paclitaxel, docetaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trastuzumab with pertuzumab, in addition to combination chemotherapy has been shown to be very effective in shrinking cancer before surgery in patients with Her2 positive locally advanced breast cancer. This trial aims to help determine which regimen may work best with the least toxicity.
    Location: 3 locations

  • Docetaxel and Degarelix in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer

    This phase II trial studies how well docetaxel and degarelix work in treating patients with newly diagnosed prostate cancer that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Androgen can cause the growth of tumor cells. Hormone therapy using degarelix may fight prostate cancer by lowering the amount of androgen the body makes and / or blocking the use of androgen by the tumor cells. Giving docetaxel and degarelix may work better in treating patients with prostate cancer.
    Location: 3 locations

  • A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies

    This is a nonrandomized, open-label, dose escalation, safety, activity, and PK study to determine the MTD and optimal dosing regimen of Oradoxel. No control group has been included.
    Location: 3 locations

  • Carboplatin and Docetaxel in Treating Participants with Estrogen Receptor Negative and HER2 Negative Breast Cancer

    This phase II trial studies how well docetaxel and carboplatin work in treating participants with estrogen receptor negative and HER2 negative breast cancer. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 3 locations

  • Implantable Microdevice for the Evaluation of Drug Response in Patients with Prostate Cancer

    This phase I trial investigates the feasibility and safety of an implantable microdevice for the evaluation of drug response in patients with prostate cancer. Implanting and retrieving a microdevice that releases up to 20 drugs directly within the prostate cancer lesion may help to evaluate the effectiveness of several approved cancer drugs against prostate cancer. Once optimized, the implantable microdevice may be able to predict the efficacy of specific drugs for each patient’s tumor and inform therapeutic decision-making.
    Location: 2 locations

  • A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

    The purpose of this study is to test the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
    Location: 5 locations

  • DKN-01 with or without Docetaxel in Treating Patients with Advanced Prostate Cancer with Elevated DKK1

    This phase Ib / IIa trial studies best dose of DKN-01 and how well it works with or without docetaxel in treating patients with prostate cancer with elevated DKK1 that had spread to other places in the body (advanced). DKN-01 is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving DKN-01 with or without docetaxel will work better in treating patients with prostate cancer with elevated DKK1.
    Location: 2 locations

  • Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)

    This study will compare the clinical activity of novel immune-oncology agents (in combination or as single agents) to standard of care in participants with relapsed / refractory advanced NSCLC. The study will initially evaluate two treatment regimens / arms. Additional regimens / arms may be added via future protocol amendment(s). Participants will be stratified by histology (squamous vs. non-squamous) and line of anti-programmed cell death ligand 1 (PD[L]1) therapy (first vs. second line). Initially, the study will evaluate the GSK3359609 inducible T-cell co-stimulator (ICOS) agonist in combination with SoC docetaxel compared to docetaxel alone (sub-study 1). SoC arm will be the common comparison arm across all sub-studies. At study start, subjects will be randomized to the study at a ratio of 1:2 to Arm 1 (docetaxel) and Arm 2 (ICOS agonist + docetaxel). The study will consist of three periods: Screening, Treatment, and Follow-Up. There will be approximately 105 participants enrolled in the study initially. Treatment will continue for approximately 2 years and participants will be followed for survival during the follow-up period.
    Location: 4 locations

  • Ceritinib and Docetaxel in Treating Patients with Stage IIIB / IV ALK-Negative and EGFR Wild-Type Non-small Cell Lung Cancer

    This phase I trial studies the best dose and side effects of ceritinib and docetaxel in treating patients with stage IIIB / IV ALK-negative and EGFR wild-type non-small cell lung cancer. Ceritinib and docetaxel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ceritinib and docetaxel may work better in treating patients with non-small cell lung cancer.
    Location: 2 locations

  • A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

    This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in patients with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: the first-line (1L) cohort will consist of patients who have not received any systemic therapy for their disease and the second-line (2L) cohort will consist of patients who progressed during or after receiving a platinum-containing regimen and a PD-L1 / PD-1 checkpoint inhibitor treatment. In each cohort, eligible patients will be assigned to one of several treatment arms.
    Location: 3 locations

  • Combination Chemotherapy and Radiation Therapy in Treating Patients with Locally Advanced HPV Positive Oropharynx Cancer

    This phase II trial studies how well combination chemotherapy followed by reduced dose chemoradiation therapy works in curing patients with locally advanced human papillomavirus (HPV) positive oropharynx cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving combination chemotherapy prior to chemoradiation therapy may result in be less early and late toxicity and side effects then standard chemoradiotherapy in HPV positive oropharynx cancer as there will be fewer side effects.
    Location: 2 locations

  • Neoadjuvant Treatment of Triple Negative Breast Cancer Patients with Docetaxel and Carboplatin to Assess Anti-tumor Activity

    This phase II trial studies how well docetaxel and carboplatin before surgery works in treating patients with stage II-III triple-negative breast cancer that has not previously been treated. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving docetaxel and carboplatin before surgery may help increase the number of patients with no evidence of cancer left after their treatment.
    Location: 2 locations

  • Stereotactic Radiosurgery and Cetuximab with or without Docetaxel in Treating Patients with Recurrent Head and Neck Cancer Previously Treated with Radiation Therapy

    This randomized phase II trial studies how well stereotactic radiosurgery and cetuximab with docetaxel work compared with stereotactic radiosurgery and cetuximab alone in treating patients with head and neck cancer previously treated with radiation therapy that has come back after a period of improvement (recurrent). Stereotactic radiosurgery, also called stereotactic body radiation therapy (SBRT), uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving stereotactic radiosurgery and cetuximab with or without docetaxel is more effective in killing tumor cells.
    Location: 2 locations

  • Intraperitoneal Docetaxel in Combination with mFOLFOX6 for the Treatment of Gastric Cancer Patients with Peritoneal Carcinomatosis

    This phase I trial evaluates the side effects and best dose of intraperitoneal docetaxel when given together with intravenous combination chemotherapy (mFOLFOX6) in treating patients with gastric cancer that has spread to the peritoneal (abdominal) surface (peritoneal carcinomatosis). Docetaxel works by inhibiting DNA, RNA, and protein creation thus preventing the growth of tumor cells. mFOLFOX6 is a combination of oxaliplatin, leucovorin, and fluorouracil that work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) kills more tumor cells. Giving docetaxel directly into the abdomen (intraperitoneal) may result in more of the drug reaching the tumor cells. Giving intraperitoneal docetaxel and intravenous mFOLFOX6 chemotherapy may be effective in treating gastric cancer patients with peritoneal carcinomatosis.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Retifanlimab with Gemcitabine and Docetaxel in Patients with Advanced Soft Tissue Sarcoma

    This phase I / II trial evaluates the effect of gemcitabine and docetaxel when given together with retifanlimab in treating patients with soft tissue sarcoma that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (advanced or metastatic) and cannot be removed by surgery (unresectable). Gemcitabine and docetaxel are chemotherapy drugs that work by killing tumor cells and interrupting their ability to divide and reproduce. Retifanlimab is an antibody, similar to the antibodies made by the immune system to protect the body from harm. Retifanlimab blocks the protein PD-1 (programmed cell death receptor 1), which usually acts as a brake on the immune system. Blocking this protein is like releasing the brakes, so the immune system can target tumor cells and destroy them. Giving gemcitabine and docetaxel together with retifanlimab may shrink or stabilize the cancer.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

    This phase I trial investigates how well pembrolizumab and chemoradiotherapy works in treating patients with gastroesophageal cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as fluorouracil, oxaliplatin and docetaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Giving pembrolizumab together with chemoradiotherapy may help to control gastroesophageal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Lenvatinib (E7080 / MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009 / E7080-G000-228 / LEAP-009)

    This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent / metastatic head and neck squamous cell carcinoma (R / M HNSCC) that have progressed after platinum therapy and a programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitor. The primary hypothesis is that pembrolizumab + lenvatinib is superior to SOC chemotherapy with respect to ORR per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review.
    Location: 6 locations

  • Gemcitabine and Docetaxel for the Treatment of Patients with Bladder Cancer

    This phase II trial studies the effect of gemcitabine and docetaxel given directly into the bladder in treating patients with non-muscle invasive bladder cancer patients who have had no prior treatment with bacillus Calmette-Guerin (BCG) (BCG-naive), the current standard of care. Chemotherapy drugs, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Combination Chemotherapy and Atezolizumab for the Treatment of Stage IB-IIIA Non-small Cell Lung Cancer

    This phase II trial estimates how many patients with stage IB-IIIA non-small cell lung cancer have measurable circulating tumor deoxyribonucleic acid (ctDNA) in their blood at baseline and unmeasurable ctDNA after receiving 1 year of chemotherapy and atezolizumab. ctDNA is genetic material in the bloodstream that comes from the tumor and is a possible marker of lung cancer returning. Chemotherapy drugs, such as cisplatin, pemetrexed, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding atezolizumab to combination chemotherapy may help kill any remaining cancer cells in patients with non-small cell lung cancer.
    Location: 2 locations

  • Docetaxel, Ramucirumab, and Pembrolizumab for the Treatment of Metastatic or Recurrent Non-small Cell Lung Cancer in Patients who have Progressed on Platinum-Doublet and PD-1 / PD-L1 Blockade Therapy

    This phase II trial studies how well docetaxel, ramucirumab, and pembrolizumab works for the treatment of non-small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent) in patients who have progressed on platinum-doublet and PD-1 / PD-L1 blockade therapy. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ramucirumab may block new blood vessel growth to reduce tumor growth. Immunotherapy with pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving docetaxel, ramucirumab, and pembrolizumab may work better in shrinking lung cancer.
    Location: 2 locations

  • CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

    This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.
    Location: 2 locations

  • Gemcitabine and Docetaxel with Radiation Therapy before Surgery for the Treatment of High Grade and Greater than 5 cm Soft Tissue Sarcoma of the Extremities

    This phase I trial investigates the side effects and best dose of gemcitabine and docetaxel when given together with radiation therapy, and to see how well the combination works before surgery in treating patients with high grade soft tissue sarcoma of the upper or lower limbs (extremities) that is over 5 cm in size. Chemotherapy drugs, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving gemcitabine, docetaxel, and radiation therapy to patients with soft tissue sarcoma of the extremities may lead to a reduction in the size of the tumor prior to surgery. It may also lead to better surgical outcomes and / or reduce the risk of the tumor spreading to other parts of the body.
    Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina

  • Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients with Stage II-III Laryngeal Cancer

    This phase II trial studies how well cisplatin, docetaxel, and pembrolizumab work in treating patients with stage II-III laryngeal cancer. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cisplatin, docetaxel, and pembrolizumab may help to control the disease.
    Location: M D Anderson Cancer Center, Houston, Texas

  • ModraDoc006 / r vs Docetaxel IV in Metastatic Prostate Cancer

    This is a multicenter phase IIb study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006 / r) in patients with metastatic castration-resistant prostate cancer, suitable for treatment with a taxane.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • FLOT and Chemoradiation before Surgery for the Treatment of Resectable Esophageal or Gastroesophageal Junction Cancer

    This phase II trial studies how well FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) and chemoradiation before surgery work in treating patients with esophageal or gastroesophageal junction cancer that can be removed by surgery (resectable). Drugs used in chemotherapy, such as 5-fluorouracil, leucovorin, oxaliplatin, docetaxel, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FLOT and chemoradiation before surgery may be an effective treatment for patients with esophageal or gastroesophageal junction cancer.
    Location: University of Colorado Hospital, Aurora, Colorado